Clinical trials: Healthy Subjects and Atopic Dermatitis Subjects
- Condition Healthy Subjects and Atopic Dermatitis Subjects
- Funder type Industry (pharma, biotech, devices)
Atopic Dermatitis
Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis
This randomized, double-blind, single center, placebo-controlled, phase 1 single ascending dose (SAD)/multiple ascending dose (MAD) study is designed to assess the safety, tolerability, PK, activity, immunogenicity, and PD of…
- Trial name
- NCT05114889
- Testing
- BSI-045B
- Where
- Australia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Biosion, Inc.
Atopic Dermatitis
Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects
The goal of this two-sequence, two-cycle, single and multiple-dose Phase I clinical trial is To evaluate the human bioequivalence of the test preparation and the reference preparation in 28 healthy chinese subjects at a single…
- Trial name
- NCT05945810
- Testing
- TLL-018 extended-release tablet, TLL-018 immediate-release tablet
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Atopic Dermatitis
LEO 29102 Single and Multiple Dose Study by Dermal Application
The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy male subjects.
- Trial name
- NCT00891709
- Testing
- LEO 29102
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Asthma, COPD
A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection
This is a Phase 1, randomized, placebo-controlled study, enrolling approximately 38 healthy adult subjects (18-65 yrs). The purpose of this study is to evaluate the safety, tolerability and PK of single ascending dose of 9MW1911…
- Conditions
- Asthma, COPD, Atopic Dermatitis
- Trial name
- NCT05170243
- Testing
- 9MW1911 Injection
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Dermatitis, Atopic
A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)
This is a Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Health Subjects, and Subjects with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT04220411
- Testing
- AR100DP1
- Where
- Taiwan
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Arjil Pharmaceuticals LLC
Atopic Dermatitis, Healthy
Assessment of Clinical, Biological and Biometrological Parameters in Adults Subjects With Atopic Dermatitis
In most recent years, the gut microbiome has been highlighted as a key player in the control of organs distant from the gut. Indeed, studies have raised evidence that gut microbiota exerts a control on various diseases including…
- Trial name
- NCT07017348
- Testing
- Clinical assessments, Biometrological measurements, Biological sampling
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Dermatitis, Atopic
Skin Irritation Study of GSK2894512 Cream
GSK2894512 is a novel anti-inflammatory agent that is currently under development for the topical treatment of atopic dermatitis and chronic plaque psoriasis.
- Trial name
- NCT02637206
- Testing
- GSK2894512 Cream, Vehicle Cream, Empty Patch
- Where
- Japan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects
The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) doses of QLM3003 compared to placebo. Also, pharmacokinetics (PK) of qlm3003 will be evaluated.
- Trial name
- NCT05932888
- Testing
- QLM3003
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis
Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis
This is a randomized, double-blind, single/multiple dose escalation, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in healthy subjects and…
- Trial name
- NCT06553209
- Testing
- CM512
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis, Healthy
Pilot Tape Harvesting Study
The main objectives of the study are: To determine if RNA recovery from tape harvesting allows for the identification of a disease gene signature (e.g., interferon [IFN] signature for lupus) or other biomarkers that may…
- Conditions
- Atopic Dermatitis, Healthy, Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus
- Trial name
- NCT02125695
- Testing
- Skin Taping, Blood Sampling, Skin Biopsy
- Where
- 2 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Biogen
Atopic Dermatitis (AD)
A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects
The study is designed to investigate the safety and tolerability of KBL697 in healthy volunteers. KBL697 has been developed as a potential new treatment for atopic dermatitis (AD).
- Trial name
- NCT04056130
- Testing
- KBL697
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- KoBioLabs
Atopic Dermatitis Eczema
A Safety, Tolerability and Preliminary Efficacy Study of FRTX-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis
FRTX-02 is an orally-available, potent and selective DYRK1A inhibitor.
- Trial name
- NCT05382819
- Testing
- FRTX-02 Capsule
- Where
- Canada
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Fresh Tracks Therapeutics, Inc.
Atopic Dermatitis
Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream
The principle aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 39652 cream is administered cutaneously as single dose to subjects with atopic dermatitis and to healthy subjects.
- Trial name
- NCT01850849
- Testing
- LEO 39652 cream, cream vehicle
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects
This study is a randomized, parallel-group, open-label Phase I clinical trial designed to compare the bioavailability and safety of subcutaneous SHR-1819 injection administered via different injection devices in healthy subjects.
- Trial name
- NCT07264335
- Testing
- SHR-1819 Injection
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Atopic Dermatitis
A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants
The primary objective of the study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) dose in a vial compared to a prefilled syringe in healthy participants.
- Trial name
- NCT06268860
- Testing
- Rocatinlimab vial injection, Rocatinlimab prefilled syringe
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Amgen
Asthma, COPD
An Evaluation of 9MW1911 Injection in Healthy Subjects
This study is a randomized, double-blind, dose-escalating phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of 9MW1911 injection in healthy subjects.
- Conditions
- Asthma, COPD, Atopic Dermatitis
- Trial name
- NCT05803902
- Testing
- Experimental drug 9MW1911
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Atopic Dermatitis
A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®
It is a randomized, double-blinded, parallel, single-dose, PhaseⅠcomparative study to evaluate the pharmacokinetics and safety of QL2108 to Dupixent® in healthy Chinese adult subjects.
- Trial name
- NCT06614907
- Testing
- QL2108 injection, Dupixent®
- Where
- China
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis
Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis
This is a phase 1, single-center, first-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of DS-2741a after subcutaneous injection in healthy Japanese male volunteers and Japanese participants with…
- Trial name
- NCT04211415
- Testing
- DS-2741a
- Where
- Japan
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo Co., Ltd.
Healthy Subjects and Atopic Dermatitis Subjects
A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis
The purpose of the study is to determine safety and tolerability of IL-31 mAB
- Trial name
- NCT01614756
- Testing
- BMS-981164
- Where
- 4 sites in United Kingdom
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Dermatitis, Atopic
Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.
A Phase 1, Open Label, Parallel-Cohort, Randomized, Fixed Sequence Study To Evaluate The Pharmacokinetic Drug Drug Interaction Between PF-04965842 and Fkuvoxamine (cohort 1) or Fluconazole (Cohort 2) in healthy subjects.
- Trial name
- NCT03634345
- Testing
- Period 1 - Day 1: PF-04965842 administered, Period 2: Cohort 1: Fluvoxamine & PF-04965842, Period 2: Cohort 2: Fluconazole & PF-04965842
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer